Lat­est news: It’s a no on uni­ver­sal boost­ers; Pa­tient death stuns gene ther­a­py field; In­side Tril­li­um’s $2.3B turn­around; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Next week is shap­ing up to be a busy one, as our ed­i­tor-in-chief John Car­roll and man­ag­ing ed­i­tor Kyle Blanken­ship lead back-to-back dis­cus­sions with a great group of ex­perts to dis­cuss the week­end news and trends. John will be spend­ing 30 min­utes with Jake Van Naar­den, the CEO of Lil­ly On­col­o­gy, and Kyle has a bril­liant pan­el lined up: Har­vard’s Cigall Kadoch, Su­san Gal­braith, the new head of can­cer R&D at As­traZeneca, Roy Baynes at Mer­ck, and James Chris­tensen at Mi­rati. Don’t miss out on the ac­tion — sign up here.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA